

Date: 30-07-2014

To,
The Secretary,
The Bombay Stock
Exchange Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai. - 400 001

The Manager (Listing
Department)
The Ahmedabad Stock
Exchange Ltd.,
Kamadhenu Complex,
Opp. Sahajanand College,
Panjarapole,
Ahmedabad

To,
The Manager (Listing
Department)
The Madras Stock
exchange,
Chennai

Sub : Outcome of the Board meeting.

The meeting of the Board of Directors of the company was held at 04:30 pm today. The out come of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.

The Board has considered and approved the Standalone and Consolidated Un-Audited Financials for the Quarter ended 30th June, 2014.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you

Yours truly,
for **TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED.**



ARVIND KUMAR BHANGADIA
Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

T. 040 2473 7370

W: www.trimurthigroup.com **CIN No: L67120AP1994PLC 018950**



TRIMURTHI
GROUP

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2014

(Rs. In Lakhs)

Particulars	3 Months ended 30-06-2014	Preceeding 3 months ended 31-03-2014	Corresponding 3 months ended 30-06-2013	Year ended 31-03-2014
	Unaudited	Audited	Unaudited	Audited
1. Net Sales / Income from Operations	145.71	139.63	109.93	484.75
2. Other Income	28.87	13.47	21.44	91.13
3. Total Income	174.58	153.10	131.37	575.88
4. Expenditure				
a. (Increase)/Decrease in stock in trade and work in Progress	3.01	20.71	(9.63)	1.07
b. Consumption of Raw Material	Nil		Nil	
c. Purchase of Traded Goods	131.71	98.31	102.51	422.95
d. Employees Cost	4.76	14.39	4.47	33.13
e. Rent	1.50	1.50	1.50	6.00
f. Depreciation	7.66	7.18	6.89	28.53
g. Other Expenditure	7.63	7.84	5.25	22.62
Total	156.28	149.93	110.99	514.30
5. Interest	0.00	0.13	0.19	0.64
6. Exceptional items	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	18.30	3.04	20.19	60.94
8. Tax Expense (Including Deferred and Finge Benefit tax)	6.02	(0.54)	6.24	19.36
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	12.28	3.58	13.95	41.58
10. Extraorindary Items	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	12.28	3.58	13.95	41.58
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	344.80	293.26	266.47	293.26
14. Earnings Per Share (EPS)				
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.15	0.05*	0.17	0.60
15. Public Share Holding				
- Number of Shares	3102200	3166200	3366200	3166200
- Percentage of shareholding	38.30%	39.09%	41.56%	39.09%
16. Promoters and promoter group shareholding				
a. Pledged / encumbered				
- No of Equity Shares	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil
a. Non encumbered				
- No of Equity Shares	4997800	4933800	4733800	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	61.70%	60.01%	58.44%	60.91%

* Weighted Average Number of Equity Shares considered

www.trimurthigroup.com **CIN No. L67120AP1994PLC018956**



TRIMURTHI
GROUP

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
CONSOLIDATED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2014

Segment Reporting

Particulars	Quarters ended			Year ended
	30/06/2014	31/03/2014	30/06/2013	31/03/2014
	Unaudited	Audited	Audited	Audited
1. Segment Revenue				
a. Pharma Business	148.02	133.27	110.45	486.39
b. Financial Services	26.51	19.83	20.92	89.48
c. Investments	0.05	0.00	0.00	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	174.58	153.10	131.37	575.88
2. Segment Profits				
a. Pharma Business	6.73	(13.32)	0.56	(19.51)
b. Financial Services	11.58	16.36	19.63	80.44
c. Investments	0.00	0.00	0.00	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	18.31	3.04	20.19	60.94
3. Capital Employed				
a. Pharma Business	70.15	413.38	339.43	413.38
b. Financial Services	1070.83	681.82	667.55	681.82
c. Investments	5.00	31.50	22.00	31.50
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	1145.98	1126.70	1028.98	1126.70

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 30-07-2014.
- The financial results for the quarter ended 30-06-2014 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 30-06-2014:
 - pending at the beginning - Nil
 - received - Nil
 - settled - Nil
 - pending at the end - Nil

Place: Hyderabad,
Date : 30-07-2014.

For Trimurthi Drugs & Pharmaceuticals Ltd.

Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,

Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com **CIN No: L67120AP1994PLC018956**

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED

UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2014

(Rs. In Lakhs)

Particulars	3 Months ended 30-06-2014	Preceeding 3 months ended 31-03-2014	Corresponding 3 months ended 30-06-2013	Year ended 31-03-2014
	Unaudited	Audited	Unaudited	Audited
1. Net Sales / Income from Operations	31.40	139.63	109.93	484.75
2. Other Income	26.51	13.47	21.44	91.13
3. Total Income	57.90	153.10	131.37	575.88
4. Expenditure				
a. (Increase)/Decrease in stock in trade and work in Progress	32.21	20.71	(9.63)	1.07
b. Consumption of Raw Material	Nil		Nil	
c. Purchase of Traded Goods	0.08	98.31	102.51	422.95
d. Employees Cost	1.47	14.39	4.47	33.13
e. Rent	0.30	1.50	1.50	6.00
f. Depreciation	7.66	7.18	6.89	28.53
## g. Other Expenditure	6.07	7.84	5.25	22.62
Total	47.80	149.93	110.99	514.30
5. Interest	0.00	0.13	0.19	0.64
6. Exceptional items	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	10.11	3.04	20.19	60.94
8. Tax Expense (Including Deferred and Finge Benefit tax)	3.50	(0.54)	6.24	19.36
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	6.61	3.58	13.95	41.58
10. Extraorindary Items	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	6.61	3.58	13.95	41.58
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	341.45	293.26	266.47	293.26
14. Earnings Per Share (EPS)				
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.08	0.05*	0.17	0.60
15. Public Share Holding				
- Number of Shares	3102200	3166200	3366200	3166200
- Percentage of shareholding	38.30%	39.09%	41.56%	39.09%
16. Promoters and promoter group shareholding				
a. Pledged / encumbered				
- No of Equity Shares	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil
a. Non encumbered				
- No of Equity Shares	4997800	4933800	4733800	4933800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	61.70%	60.91%	58.44%	60.91%

* Weighted Average Number of Equity Shares considered

W: www.trimurthigroup.com

CIN No: L67120AP1994PLC018956



TRIMURTHI
GROUP

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED JUNE, 2014

Segment Reporting


Particulars	Quarters ended			Year ended
	30/06/2014	31/03/2014	30/06/2013	31/03/2014
	Unaudited	Audited	Audited	Audited
1. Segment Revenue				
a. Pharma Business	31.40	133.27	110.45	486.39
b. Financial Services	26.51	19.83	20.92	89.48
c. Investments	0.00	0.00	0.00	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	57.90	153.10	131.37	575.88
2. Segment Profits				
a. Pharma Business	(1.47)	(13.32)	0.56	(19.51)
b. Financial Services	11.58	16.36	19.63	80.44
c. Investments	0.00	0.00	0.00	0.01
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	10.11	3.04	20.19	60.94
3. Capital Employed				
a. Pharma Business	26.33	392.88	339.43	392.88
b. Financial Services	1058.43	681.82	667.55	681.82
c. Investments	31.50	31.50	22.00	31.50
d. Trading in Shares	0.00	0.00	0.00	0.00
Total	1116.26	1106.20	1028.98	1106.20

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 30-07-2014.
- The financial results for the quarter ended 30-06-2014 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 30-06-2014:
 - pending at the beginning - Nil
 - received - Nil
 - settled - Nil
 - pending at the end - Nil

Place: Hyderabad,
Date : 30-07-2014.

For Trimurthi Drugs & Pharmaceuticals Ltd.


Managing Director

Trimurthi Drugs & Pharmaceuticals Ltd.

4-4-231/1/2 ABC, Inder Bagh, Sultan Bazar,
Hyderabad - 500 095, A.P., India

T: 040 2475 7370

W: www.trimurthigroup.com **CIN No: L67120AP1994PLC 018956**